Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India establishes two advanced research centres at IIT Hyderabad's Technology Research Park, focusing on peptide development and particle engineering to enhance global pharma innovation.
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
Navin Fluorine International rallies 80% in 2025 as CDMO revenues double, Darolutamide orders ramp up, and new capacity boosts FY26 outlook. Strong margin expansion fuels investor optimism.
Global PE giants Advent and Warburg Pincus join Blackstone, KKR, EQT in race for Encube Ethicals stake. Promoters may sell alongside Quadria Capital in potential $2.3B valuation deal.
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.